KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Shares Issued (2018 - 2025)

Historic Shares Issued for Aquestive Therapeutics (AQST) over the last 8 years, with Q3 2025 value amounting to $296000.0.

  • Aquestive Therapeutics' Shares Issued rose 5336.79% to $296000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $346000.0, marking a year-over-year decrease of 5324.32%. This contributed to the annual value of $732000.0 for FY2024, which is 177692.31% up from last year.
  • Per Aquestive Therapeutics' latest filing, its Shares Issued stood at $296000.0 for Q3 2025, which was up 5336.79% from $50000.0 recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Shares Issued high stood at $9.9 million for Q1 2021, and its period low was -$24.4 million during Q4 2021.
  • Moreover, its 5-year median value for Shares Issued was $417500.0 (2024), whereas its average is $95428.6.
  • Over the last 5 years, Aquestive Therapeutics' Shares Issued had its largest YoY gain of 1379354.84% in 2021, and its largest YoY loss of 49666.83% in 2021.
  • Quarter analysis of 5 years shows Aquestive Therapeutics' Shares Issued stood at -$24.4 million in 2021, then skyrocketed by 84.55% to -$3.8 million in 2022, then skyrocketed by 100.21% to $8000.0 in 2023, then surged by 2312.5% to $193000.0 in 2024, then skyrocketed by 53.37% to $296000.0 in 2025.
  • Its last three reported values are $296000.0 in Q3 2025, $50000.0 for Q2 2025, and $193000.0 during Q3 2024.